TY - JOUR
T1 - Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis
AU - Sommer, Rafael Canani
AU - Hata, Junichi
AU - Rimkus, Carolina de Medeiros
AU - Klein da Costa, Bruna
AU - Nakahara, Jin
AU - Sato, Douglas Kazutoshi
N1 - Funding Information:
RCS has received a scholarship (iniciação científica) from CNPq/Brazil and FAPERGS/Brazil JH has nothing to disclose BKC received a scholarship from CNPq/ Brazil and from the Brazilian Committee for Research and Treatment of Multiple Sclerosis. Received speaking honoraria from Libbs, travel support from Merck, Roche and Biogen, support for medical education from Novartis and, research support from TEVA. JN received a Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI 18K07508), institutional research grants from Keio University, collaborative research fund from Biogen, research scholarships from Astellas, Böehringer-Ingelheim, Daiichi-Sankyo, Eisai, JB, Kyowa-Kirin, Mitsubishi-Tanabe, Novartis, Otsuka, Pfizer, Sanofi, Shionogi and Sumitomo Dainippon, and speaker honraria from Abbvie, Alexion, Astellas, Biogen, CSL-Behring, Daiichi-Sankyo, Eisai, Fujimoto Pharma, JB, Mitsubishi-Tanabe, Novartis, Otsuka, Sanofi, Sumitomo Dainippon and Takeda. DKS received a scholarship from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, a Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI 15K19472), research support from CNPq/Brasil (425331/2016–4 and 308636/2019–8), TEVA, Merck, and Euroimmun AG for investigator initiated studies, and speaker honoraria from Biogen, Novartis, Genzyme, TEVA, Merck, Roche and Bayer, and has been an advisory board member for Shire, Roche, TEVA, and Merck.
Funding Information:
We would like to acknowledge TEVA for supporting the investigator-initiated study – EMOCEMP (NCT03087136) that supported a pilot study with qMM and this review.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/2
Y1 - 2022/2
N2 - Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The remyelination process requires the activation, migration and differentiation of oligodendrocyte progenitor cells (OPC) in demyelinated areas. The metabolic dysfunction in chronic demyelinating lesions impairs the activation of OPCs, the myelin debris clearance by microglia decreases with age, along with diminished secretion of factors promoting OPC differentiation. Conventional magnetic resonance imaging (MRI) sequences have limited ability to differentiate unmyelinated and remyelinated lesions. Advanced MRI sequences based on magnetization transfer ratio (MTR), myelin water fraction (MWF) and diffusion tensor imaging (DTI) have been used to evaluate remyelination in clinical trials. More recently, the q-space myelin map (qMM) has been used on experimental and exploratory clinical studies. The improvement of myelin-specific MRI sequences with high reliability and standardization among centers will allow a more accurate evaluation of new therapies to improve remyelination. These new remyelination promoting treatments alone or in combination with current options may reduce the risk of long-term disability in MS.
AB - Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The remyelination process requires the activation, migration and differentiation of oligodendrocyte progenitor cells (OPC) in demyelinated areas. The metabolic dysfunction in chronic demyelinating lesions impairs the activation of OPCs, the myelin debris clearance by microglia decreases with age, along with diminished secretion of factors promoting OPC differentiation. Conventional magnetic resonance imaging (MRI) sequences have limited ability to differentiate unmyelinated and remyelinated lesions. Advanced MRI sequences based on magnetization transfer ratio (MTR), myelin water fraction (MWF) and diffusion tensor imaging (DTI) have been used to evaluate remyelination in clinical trials. More recently, the q-space myelin map (qMM) has been used on experimental and exploratory clinical studies. The improvement of myelin-specific MRI sequences with high reliability and standardization among centers will allow a more accurate evaluation of new therapies to improve remyelination. These new remyelination promoting treatments alone or in combination with current options may reduce the risk of long-term disability in MS.
KW - Imaging
KW - Magnetic resonance
KW - Multiple sclerosis
KW - Myelin
KW - Remyelination
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85119578976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119578976&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2021.103407
DO - 10.1016/j.msard.2021.103407
M3 - Review article
C2 - 35216787
AN - SCOPUS:85119578976
SN - 2211-0348
VL - 58
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 103407
ER -